European Tech Sovereignty

Infineon opened its €5bn Dresden power-chip fab on 2 July, months early, the first Chips Act flagship to deliver after Magdeburg and Crolles collapsed. The win lands at the power and analog node, not the leading-edge logic where Europe's real dependency sits. Brussels' court win over Google, a stalled Cohere-Aleph Alpha merger and a fresh UK procurement round fill out a week of sovereignty machinery grinding unevenly forward.

The European Parliament cleared the digital euro into final trilogue talks on 23 June, the day after the US Senate voted to ban its own central bank digital currency for four years. Over the same fortnight Washington pressed the fronts Europe cannot yet supply itself: a bill over ASML's China sales, a US order pulling Anthropic's top models offline, and a 100% digital-tax tariff threat. Mistral's push toward a ~€20bn valuation is Europe's bet on building the substitutes in time.

Two weeks after the EU adopted its sovereignty package, three mid-June data points from inside the bloc exposed the gap between the law and the reality it targets. The Commission's own scorecard put semiconductor share at 9% against a 20% goal. Bruegel costed the cloud law at up to 86bn euros. And Brussels reached for antitrust, not its flagship cloud law, to reopen WhatsApp to rival AI.

On 3 June Brussels adopted the Cloud and AI Development Act and, the same afternoon, EU ambassadors cleared the Commission to join the US-led Pax Silica chip alliance with a 40bn dollar AI-chip commitment. France objected; Germany, Italy and the Netherlands backed it. The UK answered with a 1.1bn pound hardware plan as the silicon gap under both moves came into view at Dresden.

The College of Commissioners is set to adopt the Tech Sovereignty Package today, 3 June, on its fourth scheduled date. But the week's binding action came from elsewhere: the Netherlands blocked a US cloud takeover, Mistral won Airbus and BMW on merit, and France's own G7 chairmanship dropped cloud sovereignty from the communique it wrote.

The Tech Sovereignty Package did not adopt on 27 May as promised; it slipped a third time to a tentative 3 June after the US ambassador called it a red line. France now chairs the G7 in two days with nothing to table. Mistral buys into industrial AI while wearing a USTR target, and the digital euro becomes the one instrument still on schedule.

Europe's tech sovereignty machine enters a 10-day delivery window. On 27 May the Commission adopts the Cloud and AI Development Act alongside a revamped Chips Act. On 29 May France chairs the G7 Digital Ministerial at Bercy. The 7 May AI Omnibus deal has already split the AI Act enforcement clock in two.

Two weeks after Sovereign Tech Europe declared sovereignty moving from concept to construction, the construction came from a trade body and a retail conglomerate. The Commission's tech-sovereignty package slipped to 27 May. Seven European CEOs, Mistral included, told von der Leyen on 5 May to stop adding rules.

The inaugural Sovereign Tech Europe summit opened in Brussels today with 45 speakers, no European AI model companies, and only cabinet-level Commission presence. In one week the machinery of European sovereignty has become visible: four named cloud providers, seven DSIT investees, an open DMA consultation. Every instrument carries a US dependency somewhere inside it.

Europe and Britain converted sovereignty rhetoric into binding instruments in a single week: a €180m pan-EU sovereign cloud framework, the first UK Sovereign AI investees including defence-AI firm Cosine, and a DMA order forcing Google to share search data by 27 July. The three mechanisms expose a structural contradiction between shared European dependency, national British isolation, and an uncoordinated regulatory calendar.

Two of the EU Chips Act's three flagship fabs have stalled, leaving the bloc's 20% global market share target effectively dead. Mistral is building Europe's closest thing to a sovereign AI champion, but the continent's sovereignty gap remains an implementation gap: the right diagnosis, the right prescriptions, and an 11.2% delivery rate.